NCAP Medical (a sub of NCAP Technologies)

Breakthrough Technology
The NeuroCuple® device leverages nano-capacitor technology to intercept and redirect pain signals, reducing intensity without drugs. Clinical studies, including an NIH-funded trial at the University of Pittsburgh Medical Center, show a 34% reduction in postoperative pain and a 52% decrease in opioid refill requests for total knee replacement patients.

Critical Market Need
Over 50 million Americans suffer from chronic pain, with opioid dependency claiming approximately 100,000 lives annually. The annual cost of pain management in the US is estimated between $560-$635 billion, including direct healthcare cost and lost productivity; making it higher than the cost of treating cancer, heart disease, and diabetes combined. NeuroCuple® offers a safe, non-invasive, and cost-effective alternative, meeting the urgent demand for opioid-sparing solutions.

Proven and Safe
FDA-registered and manufactured in ISO-compliant facilities, NeuroCuple® devices demonstrate no adverse effects. Devices are currently being sold to the consumer market through licensee agreements, and royalties are received for each unit sold. With pending FDA Class II clearance for surgical and chronic pain applications in 2025–2026, clinical expansion is planned.

Scalable Growth
Targeting 1.3 million knee replacements, 1.2 million C-sections, and over 5 million wisdom teeth extractions annually in the U.S., NCAP is scaling production and pursuing Medicare reimbursement. Global markets offer 1.5 times the U.S. opportunity. Applications have been filed with the FDA to address post-op back surgery, post-op wisdom teeth removal, and post-op C-section patients. Additional trials are planned to support new products for 3–5 years.

Strong Leadership and Milestones
Led by CEO Anthony Sutera and a seasoned team, NCAP has secured NIH STTR grants, 29 patents, and partnerships with top institutions like UPMC. Ongoing trials and planned FDA clearances position the company for growth. The Chief Medical Officer, Senthil Sadhasivam, MD, MBA, MPH, is known globally as a top research doctor and has received substantial NIH grant funding.